News

2025 Research Program

November 1, 2024

CureBRCA will consider funding BRCA-related initiatives that involve prevention, detection, screening, and/or treatment for men at risk for BRCA-related cancers. Applications are due by March 15, 2025. Interested parties are asked to submit an optional Notice of Intent (NOI).

News

2025 Funding Announcement

October 16, 2024

The BRCA Research & Cure Alliance (CureBRCA) will be launching its 2025 Research Awards Program soon. Full information regarding types of applications being sought, eligibility, funding details, evaluation process, and the online application process will be posted here on November 1, 2024.

News

BRCA1, BRCA2, and Associated Cancer Risks and Management for Male Patients, A Review

July 25, 2024

Published by: JAMA Oncology

This peer-reviewed article’s lead author is Heather Cheng, MD, PhD, with key contributions from Kara Maxwell, MD, PhD, Bryson Katona, MD, PhD, and Jeffrey Shevach, MD, along with a distinguished team of international experts.

News

BRCA1/2 Genetic variants may increase risk for other cancers besides breast, ovarian, prostate and pancreatic, large study finds

June 13, 2024

People who test positive for BRCA1/2 genetic variants may be at risk for other types of cancer beyond those previously known, according to a study being presented at the National Society of Genetic Counselors (NSGC) 42nd Annual Conference.

News

BRCA mutations are associated with worse treatment outcomes in mCRPC

March 8, 2024

In patients with metastatic castration-resistant prostate cancer, early genetic testing may help personalize treatments in the first-line as a study suggests.

News

2024 Funding Announcement

January 24, 2024

In 2023, the BRCA Research & Cure Alliance (CureBRCA) initiated an open call for research applications resulting in $2.3 million distributed among five essential research endeavors. It is our hope that this research could be pivotal to understanding prostate cancer risk, prevention, and interception and bring hope to the multitude of BRCA gene mutation carriers.

News

23andMe Cleared to Report 41 More BRCA Mutations

August 31, 2023

The U.S. Food and Drug Administration (FDA) has approved 23andMe, which makes at-home genetic tests, to report the presence of 41 more variants, or mutations, of the BRCA1 and BRCA2 genes that are linked to a higher risk of developing breast, ovarian, prostate, and pancreatic cancers.

News

FDA approves niraparib and abiraterone acetate plus prednisone for BRCA-mutated metastatic castration-resistant prostate cancer

August 29, 2023

On August 11, 2023, the Food and Drug Administration approved the fixed dose combination of niraparib and abiraterone acetate (Akeega, Janssen Biotech, Inc.), with prednisone, for adult patients with deleterious or suspected (CONT)

News

FDA approves talazoparib with enzalutamide for HRR gene-mutated metastatic castration-resistant prostate cancer

August 29, 2023

On June 20, 2023, the Food and Drug Administration approved talazoparib (Talzenna, Pfizer, Inc.) with enzalutamide for homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC).

News

2023 Grant Recipients

June 30, 2023

CureBRCA Funds BRCA Prostate Cancer Research – Funded research includes grants to U.S. and international academic institutions: projects include research, screening, treatment, and outreach efforts for men with BRCA genetic mutations.